#Middle East #Jordan #Amman #MS Pharma #Olayan Financing

MS Pharma and Olayan Financing Company Forge Strategic Partnership

In a significant development for the pharmaceutical industry in the MENA region, MS Pharma has announced that the Olayan Financing Company (OFC) has acquired a minority stake in the company. This move is designed to support MS Pharma in its ambitious growth plans, particularly in Saudi Arabia and beyond. The investment focuses on enhancing MS Pharma's capabilities in biologics and expanding its production capacities, while also solidifying its supply chain resilience across the region.

The official announcement was made during a signing ceremony that showcased the collaboration between key executives from both companies. The transaction involves MS Pharma issuing new equity in exchange for a substantial cash investment from OFC, granting the latter a minority interest in the company. This investment is anticipated to bolster MS Pharma's financial standings and provide the flexibility necessary to pursue its strategic goals.

Ghiath Sukhtian, Chairman of MS Pharma, expressed his excitement about the partnership. He emphasized that welcoming OFC as a partner aligns with MS Pharma’s commitment to innovation and regional expansion. "Their operational expertise and established presence in Saudi Arabia will create significant value for MS Pharma and all our stakeholders," Sukhtian stated. He highlighted the vital role played by the company’s dedicated workforce in achieving this milestone, attributing the success to their leadership and continuous efforts.

Kalle Kaend, CEO of MS Pharma, also shared his enthusiasm for the new chapter the collaboration represents. He remarked, "This investment comes at a pivotal moment for MS Pharma, allowing us to deepen our expertise in biological products and expand our reach throughout Saudi Arabia and the MENA region. We look forward to leveraging OFC's extensive network to achieve our ambitious goals while strengthening our organization to deliver long-term value to patients, partners, and our employees."

Nabeel Al-Amudi, CEO of OFC, acknowledged MS Pharma's prominence in the pharmaceutical domain, particularly its strong capabilities in generics and biologics. He is excited about the partnership's potential impact on MS Pharma's growth trajectory in line with OFC's long-term investment philosophy.

This collaboration builds upon MS Pharma’s leadership in the biosimilars sector in Saudi Arabia, where its biologics manufacturing facility was the first in the kingdom to receive SFDA-GMP certification for biologics production. The company aims to be the first local provider of biologics in the Saudi market within the year, marking a significant achievement and reflecting its dedication to localization within the framework of Saudi Arabia's National Biotechnology Strategy and Vision 2030.

MS Pharma is committed to delivering high-quality biological therapies in the region and continues to work closely with local and international health authorities, ensuring adherence to the highest standards of regulatory excellence and quality. In addition to its ambitious growth plans, MS Pharma seeks to deepen cooperation with global development and licensing partners while offering its production capabilities to support exports into international markets.

About MS Pharma

With its headquarters in Amman, Jordan, MS Pharma is a leading regional pharmaceutical company in the MENA region, specializing in the development, production, and distribution of a diverse portfolio of generics and biological therapies. The company operates five manufacturing facilities in Jordan, Algeria, and Saudi Arabia, including a recently launched biologics plant that serves the entire MENA market. Committed to improving patient access to high-quality, affordable medications, MS Pharma employs over 2,000 professionals across 12 countries.

For more information about MS Pharma, please visit www.mspharma.com.

About Olayan Financing Company (OFC)

Established in 1947, Olayan Financing Company (OFC) serves as a leading multinational firm with a diverse portfolio spanning over 32 businesses and global investments across Saudi Arabia, the Middle East, North Africa, Turkey, and India. OFC’s investments encompass publicly listed stocks, private equity, strategic partnerships, and real estate, and it draws upon a long-standing history of successful collaborations. Their multicultural workforce comprises over 14,500 skilled professionals from more than 60 countries. OFC is actively engaged in supporting Saudi Arabia's Vision 2030 goals, focusing on economic diversification, local value creation, and talent development.

For more information, visit www.ofc.com.